Generic filters

OGEN – Oragenics Inc

Not Compliant

The company’s impure earnings are more than 5% of its total revenues.

Oragenics, Inc. is a development-stage company that is focused on fighting infectious diseases, including coronaviruses and multidrug-resistant organisms. The Company’s lead product, NT-CoV2-1, is an intranasal immunization vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. Its other product candidates include Terra CoV-2 and Antibiotics. Terra CoV-2 is an intramuscular vaccine candidate (plasmid + adjuvant) to provide long-lasting immunity against SARS-CoV-2. Antibiotics is a semi-synthetic analogs of MU1140, which is a member of lantibiotic class of antibiotics. The Company, through its wholly owned subsidiary, Noachis Terra, Inc. (Noachis Terra), is engaged in the research and development of its Terra CoV-2 and NT-CoV2-1 vaccine product candidates. It is also developing semi-synthetic lantibiotic analogs that may be effective against systemic Gram-positive multidrug infections, and analogs that may be effective in treating Gram negative infections.


Debt ÷ Market cap (MC)4.73
Non-Compliant Assets ÷ MC
Impure Income (incl. Interest)87.18
Impure Income%
Interest Income87.18%

Found the Stock You’re Looking For? Open an Account Today!

Opening an account has never been easier! Please fill out the form here and an advisor will be in touch to walk you through the process!

Still have some further questions?